RenovoGem™ Patients had Greater than 65% Reduction in Side Effects, which can Include Nausea, Fatigue, and Reduced White Blood Cells During Pancreatic Cancer Treatment
These Data and Additional Secondary Endpoint Analyses to be Presented at American Association for Cancer Research (AACR) Annual Meeting on April 17, 2023
https://finance.yahoo.com/news/renovorx-announces-positive-data-phase-123000071.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.